Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
Important Content Reminder:
-
Based on recognition of its own value and confidence in future development, Shenzhen Xinlitai Pharmaceutical Co., Ltd. plans to repurchase shares through centralized bidding. The specific details are as follows:
(1) Total amount and source of funds for the repurchase: not less than RMB 300 million (inclusive) and not more than RMB 500 million (inclusive). The source of funds will be the Company's own funds and self-raised funds.
(2) Price range for the repurchase: The repurchase price will not exceed RMB 45 per share (inclusive). The specific repurchase price will be determined by the management authorized by the board of directors during the implementation period, taking into account the Company's stock price, financial status, and operational conditions. If the Company implements stock dividends, capital reserve transfers, cash dividends, rights issues, or other matters affecting stock rights during the repurchase period, the upper limit of the repurchase price will be adjusted accordingly from the date of the stock rights adjustment in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange.
(3) Scale of the repurchase: If calculated based on the upper limit of the repurchase amount and price, the estimated number of shares that can be repurchased is approximately 11,111,111 shares, accounting for about 1.00% of the Company's currently issued total share capital; if calculated based on the lower limit of the repurchase amount and the upper limit of the repurchase price, the estimated number of shares that can be repurchased is approximately 6,666,666 shares, accounting for about 0.60% of the Company's currently issued total share capital.
(4) Purpose of the repurchase: The repurchased shares are intended to be used as a source for future implementation of equity incentives or employee stock ownership plans. If the repurchased shares are not used for equity incentives or employee stock ownership plans within the legally prescribed period after the completion of the repurchase, the unused portion will be legally canceled.
(5) Implementation period: The implementation period for the share repurchase will be no more than 12 months from the date the board of directors approves this repurchase plan.
(6) Type of shares to be repurchased: The shares to be repurchased are the ordinary shares (A shares) issued by the Company. If the state adjusts relevant policies, this share repurchase plan will be implemented according to the adjusted policies. -
Whether relevant shareholders have any plans to reduce their holdings: As of the date of this report, the Company's directors, senior management, controlling shareholders, actual controllers, shareholders holding more than 5%, and their concerted actors have no clear plans to reduce their holdings within the next three or six months. If these individuals have any plans to reduce their holdings subsequently, the Company will fulfill its information disclosure obligations in a timely manner according to relevant regulations.